BAILII is celebrating 24 years of free online access to the law! Would you consider making a contribution?
No donation is too small. If every visitor before 31 December gives just £1, it will have a significant impact on BAILII's ability to continue providing free access to the law.
Thank you very much for your support!
 |
[Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback] | |
United Kingdom Intellectual Property Office Decisions |
||
|
You are here: BAILII >> Databases >> United Kingdom Intellectual Property Office Decisions >> GlaxoSmithKline (Patent) [2012] UKIntelP o50612 (19 December 2012) URL: http://www.bailii.org/uk/cases/UKIntelP/2012/o50612.html Cite as: [2012] UKIntelP o50612 |
||
[New search] [Printable PDF version] [Help]
Summary
The Hearing Officer found that SPC/GB08/046 and SPC/GB11/043 are not allowable with the product definitions as they currently stand, as neither of these definitions comply with Article 1(b). The Hearing Officer provided the applicant with an opportunity to amend either or both of the product definitions in these applications, believing that at least one of these applications could then proceed to grant. The applicant was given until 31st January 2013 to provide product definitions which satisfied the examiner. If the applicant fails to provide satisfactory product definition(s) by the given date, then the application(s) will be rejected having regard to Article 10(2) of the Regulation. The Hearing Officer did not find that SPC/GB11/043 could be stayed.
